Predictors of immunotherapy benefit in Merkel cell carcinoma.

Kacew, Alec J; Dharaneeswaran, Harita; Starrett, Gabriel J; Thakuria, Manisha; LeBoeuf, Nicole R; Silk, Ann W; DeCaprio, James A; Hanna, Glenn J

Kacew, Alec J; Dharaneeswaran, Harita; Starrett, Gabriel J; Thakuria, Manisha; LeBoeuf, Nicole R; Silk, Ann W; DeCaprio, James A; Hanna, Glenn J.

Afiliação

Kacew AJ; GJS Associated with Laboratory of Cellular Oncology, CCR/NCI, Bethesda, MD, USA.
Dharaneeswaran H; Dana-Farber Cancer Institute, Boston, MA, USA.
Starrett GJ; These authors contributed equally to this work.
Thakuria M; GJS Associated with Laboratory of Cellular Oncology, CCR/NCI, Bethesda, MD, USA.
LeBoeuf NR; Dana-Farber Cancer Institute, Boston, MA, USA.
Silk AW; These authors contributed equally to this work.
DeCaprio JA; GJS Associated with Laboratory of Cellular Oncology, CCR/NCI, Bethesda, MD, USA.
Hanna GJ; Dana-Farber Cancer Institute, Boston, MA, USA.

Oncotarget ; 11(47): 4401-4410, 2020 Nov 24.

Article em En | MEDLINE | ID: mdl-33315984

Palavras-chave

Merkel cell carcinoma; cancer; genomics; immunotherapy; precision medicine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Oncotarget Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google